BMS/Pfizer’s Eliquis On Priority Review Path Toward March 2012 Approval

Priority review designation for the Factor Xa inhibitor suggests FDA sees it as a major treatment advance over Pradaxa and Xarelto in reducing the risk of stroke among atrial fibrillation patients.